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1. Introduction
A recent JBI article on literature-based discovery [1]
claims to identify many tens of medically related potential
‘discoveries’ for three speciﬁc medical problems (Alzhei-
mer’s, Migraine, Schizophrenia) using a semi-automated
software approach. The article presents three speciﬁc ‘dis-
covery’ examples, and statistics for the remainder. In the lit-
erature-based discovery context, a discovery represents the
linking of two or more concepts that had never previously
been linked in order to produce novel, interesting, plausible,
and intelligible knowledge, and an innovation represents the
exploitation or implementation of two ormore concepts that
had been linked previously but were not being exploited. By
showing that the concepts had been linked previously in all
three cases (in major widely available literatures), this letter
will demonstrate that the three speciﬁc claimed discoveries
are neither discoveries nor innovations.
2. Background
The authors [1] present a literature-based discovery sys-
tem called LitLinker that incorporates knowledge-based
methodologies with a statistical method. The literature-
based discovery beginswith a starting term (e.g., Alzheimer’s
Disease), then uses a text mining process to ﬁnd a set of link-
ing terms (e.g., Neurotransmitters) that are directly corre-
lated with the starting term, and uses the same text mining
process to identify a set of target terms that are correlated
with each linking term (e.g., Endocannabinoids). Finally,
LitLinker ranks the target terms by the number of linking
terms that connect the target term to the starting term.
In searching the database, LitLinker uses MESH terms
(i.e., the Medline taxonomy) as the representation of the
content of the documents and performs searches on them
to collect the literatures. To ﬁnd correlations, LitLinker
calculates the probability of a term appearing in a literature
by dividing the number of documents of the literature in
which the term appeared by the total number of documents
in the literature. Those terms with distances between the
probability of a MESH term in a speciﬁc literature and
the general distribution of this MESH term in the back-
ground set of literatures larger than a pre-deﬁned threshold
are marked as the correlated terms to the starting or linking
term.
The authors used the following approach to evaluate all
correlations (potential discoveries) that LitLinker gener-
ated. They divided Medline into two parts: a baseline liter-
ature including only publications before January 1, 2004,
and a test literature including only publications between
January 1, 2004 and September 30, 2005. They ran LitLin-
ker on the baseline literature and checked the generated
connections in the test literature.
They reported results for three medical problems: Alz-
heimer’s Disease, Migraine, and Schizophrenia. They used
precision and recall as key evaluation metrics. Precision for
starting term i is deﬁned as the ratio of (Ti union Gi)/Ti,
and recall for starting term i is deﬁned as the ratio of (Ti
union Gi)/Gi, where Ti is the set of target terms generated
by LitLinker for the starting term i, and Gi is the set of
terms in the gold standard created from the test literature
of starting term i. The gold standard was deﬁned as the
MESH terms in the test literature not in the baseline liter-
ature and ﬁltered for appropriate semantic group.
Precision-time graphs show precision increasing with
time to about .06 for Alzheimer’s Disease, .025 for Mi-
graine, and .075 for Schizophrenia. Recall-time graphs
show recall oscillating with time, with approximate mean
values of about .22 for Alzheimer’s Disease, .43 for Mi-
graine, and .14 for Schizophrenia. These appear on the sur-
face to be quite reasonable results, if in fact the target terms
in the gold standard are true potential discoveries. The
authors provide one speciﬁc example of potential discovery
for each of the three diseases examined.
3. Analysis
I will examine the three speciﬁc ‘discoveries’ listed. The
ﬁrst example listed (for Alzheimer’s Disease) was the
MESH term endocannibinoids, and the authors referenced
a recent paper by a Spanish group [2] about the possible
role of the endocannibinoid system in Alzheimer’s Disease.
The authors state: ‘‘Although there has been no prior
published work [before 2004-RNK] on the potential
connection between endocannibinoids and Alzheimer dis-
ease, LitLinker could identify it by analyzing existing con-
nections in the medical literature’’.
One of the references in [2] is a published work from
2003 that relates endocannabinoids to Alzheimer’s Disease
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[3]. Additionally, entering the query ‘‘endocannabinoids
and Alzheimer’s’’ in Medline yields three additional pa-
pers published prior to 2004 [4–6]). Both terms were in
the Abstract, but not necessarily in the MESH terms.
There is a well-known eﬀect in information retrieval called
the indexer eﬀect (e.g. [7]), whereby errors in classiﬁcation
and/ or omission are made by third-party indexers. Addi-
tionally, there is a latency period before new Medline arti-
cles are indexed in MESH. This is one of the dangers of
relying on MESH terms solely, as the authors have done,
and requires extreme levels of checking if the results are
to be credible.
Additionally, a check of these papers in the Science Cita-
tion Index (SCI) shows that there were seven papers pub-
lished before 2004 that cited the Fernandez-Ruiz paper.
Also, there was an additional paper in the SCI identiﬁed
that was retrieved with the above query [8], and there were
fourteen papers published before 2004 that cited the Marsi-
cano et al. paper [8]. And this is probably the tip of the ice-
berg. There are obviously other ways to refer to
endocannabinoids (e.g., anandamide, arachidonoyl glyc-
erol, noladin ether) and simple searches involving these
terms generated a few more papers containing links be-
tween endocannibinoids and Alzheimer’s. In sum, we
would not call this a discovery, or even an innovation, be-
cause the links between endocannibinoids and Alzheimer’s
were established well before 2004. In this particular exam-
ple, these links were known by a large number of people.
Because of space limitations, I will only comment brieﬂy
on the other two purported speciﬁc ‘discoveries’, since even
one counter-example is all that is necessary to refute a ‘dis-
covery’ claim. The second speciﬁc ‘discovery’ example is
the connection between AMPA receptors and Migraine.
The authors summarized the discovery that LitLinker
found as ‘‘LY293558 is promising for Migraine treatment
[1]’’. I entered the query ((LY293558 OR AMPA) AND
MIGRAINE) in both Pubmed and the Science Citation In-
dex. Seven papers published before 2004 were identiﬁed
that linked AMPA to Migraine, four of which are refer-
enced here [9–12]. One of the pre-2004 papers [9] was pub-
lished by the authors of the post-2003 paper that contained
the above ‘discovery’ statement. The title of [9] is rather
conclusive: ‘‘A double-blind, placebo-controlled study to
investigate the eﬃcacy and tolerability of 1.2 mg/kg intra-
venous LY293558 versus 6 mg subcutaneous sumatriptan
versus placebo in patients with an acute migraine attack’’.
Again, this is the tip of the iceberg. No proxy terms were
used for AMPA/LY293558 in the query, no citing papers
were examined, and no patents were examined.
The third speciﬁc ‘discovery’ example is the use of secre-
tin to treat Schizophrenia. The authors summarize the dis-
covery as ‘‘LitLinker could automatically identify the
potential connection between secretin and Schizophrenia.
However, in a 1999 patent [13], the following links between
secretin and Schizophrenia are established.
‘‘In addition to this eﬀect on the digestive function,
secretin also appears to improve the abnormal brain activ-
ity in individuals having symptoms of autism. The in-
creased blood ﬂow in the brain detected during a SPECT
scan after administering secretin in EXAMPLE 1 supports
this theory. While causing pancreatic secretions, secretin
also stimulates the production of cholecystokinin (CCK).
Deﬁciencies in CCK have been linked to other neurological
disorders, such as schizophrenia, and CCK production has
been found to be related to levels of the neurotransmitter
serotonin. Thus, secretin may be indirectly related to the
body’s natural production of serotonin. The increase in
serotonin levels in the blood after the procedure in EXAM-
PLE 1 supports this relationship between secretin and
serotonin.’’
‘‘Accordingly, the method of treating autism by adminis-
tering secretin and/or causing the body to naturally secrete
required amounts of secretin corrects the secretin deﬁ-
ciency, improving the digestive functions in autistic patients
previously experiencing intestinal diﬃculties and improving
communication, cognition, and socialization capabilities of
autistic patients. Since other neurological disorders, such as
depression, obsessive–compulsive disorder, Alzheimer’s,
allergies, anorexia, bulimia, schizophrenia, also involve
abnormal modulation of neurotransmitter levels, these dis-
orders may also be treatable with secretin.’’
4. Discussion and conclusions
Literature-based discovery is a noble goal, and if it can
be implemented on a large scale, it will be an enormous
achievement. LitLinker, with perhaps some modiﬁcations,
might be a solution for semi-automating literature-based
discovery, but it was not demonstrated by the three exam-
ples from reference [1].
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Reply
Response to ‘‘Validating discovery in literature-based
discovery’’
Dr. Kostoﬀ’s letter illustrates how challenging it is to
evaluate discovery systems, such as the LitLinker system
in the paper that he critiqued. It is diﬃcult to predict the fu-
ture, and it is perhaps even more diﬃcult to determine
whether a system can predict the future accurately. In our
critiqued paper, we attempted to accomplish both diﬃcult
tasks—using LitLinker to predict disease–chemical correla-
tions that would hold in the future, and evaluatingwhether it
could predict the future accurately. Our paper is one of the
few papers that presents results from a quantitative evalua-
tion of a literature-based discovery system because no one
has devised a perfect way to perform such evaluations.
One key question is particularly diﬃcult to answer: when
is something ‘‘known’’? In this particular situation, we need
to knowwhen a correlation between a disease and some sub-
stance becomes ‘‘known’’, and thus is a candidate for discov-
ery if a discovery system is run on material before that time.
Is something known when someone suggests that there
could be a connection? Is it when several researchers believe
that there is a connection? Is it whenmost researchers believe
that there is a connection? Is it when knowledge of this con-
nection aﬀects clinical practice? Using the best level of evi-
dence from a medical professional’s standpoint, a
perceived correlation is a trusted one that should aﬀect clin-
ical practice if it holds in a meta-analysis of multiple, large-
scale, well-designed randomized controlled trials [1]. If we
require that level of evidence, then none of our ‘‘discoveries’’
are trustworthy even today, and they certainly were not be-
fore January of 2004, the end point for the run of LitLinker.
The appropriate deﬁnition of ‘‘known’’ for these discovery
systems is probably somewhere between the two extremes.
Thus, a main issue for any discovery system is where to
draw the known vs. unknown line or where to set the dis-
covery threshold. In our paper, we chose to deﬁne a known
correlation as any correlation that occurs at least once
among the MeSH terms in the MEDLINE literature. As
Dr. Kostoﬀ points out, we could have been even more con-
servative in deﬁning a discovery threshold.
Let’s look at each of the three discovery cases that he
critiques in detail. His ﬁrst example is of the correlation
between endocannibinoids and Alzheimer’s disease. As
we stated in our article, no documents in MEDLINE
before 2004 contain both MeSH terms [2]. However, as
Dr. Kostoﬀ pointed out, a search for those terms in the ab-
stract does yield three papers [3–5]. In these documents,
Neuroprotective Agents was the only MeSH term that
appeared to link the correlations. In contrast, LitLinker sug-
gested nine terms to link endocannibinoids and Alzheimer’s
disease that could provide a fruitful direction for research.
Three of those linking terms were used in the example we
gave to illustrate LitLinker’s discovery [6]. The other docu-
ment that Dr. Kostoﬀ refers to does not mention Alzhei-
mer’s disease in the MEDLINE record [7]; thus, it would
be diﬃcult for any automated process to identify.
For the second example of AMPA receptors and Mi-
graine, a search in MEDLINE before 2004 using the corre-
sponding MeSH terms yields no papers. In the list of
papers that Dr. Kostoﬀ cites as evidence that this correla-
tion was known prior to 2004, one is not in MEDLINE
[8], and one does not contain either AMPA or LY293558
in the abstract [9]. Thus, it is diﬃcult to see how an auto-
mated search could ﬁnd those papers.
For the third example of secretin and Schizophrenia,
there were no papers published in MEDLINE before
2004 with the corresponding MeSH terms, nor were there
any that included the terms or any of their synonyms in
the abstract or title. The only example that Dr. Kostoﬀ
provided was a patent. Given the poor accessibility, lim-
ited peer review, and prevalence of provisional patents,
we see no need to require a patent search in addition
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